Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Has Average Target Price of $74.44 According to Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $74.44.

A number of equities analysts recently issued reports on ELVN shares. JonesTrading raised their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Guggenheim dropped their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Barclays initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on Enliven Therapeutics in a report on Thursday, October 1st. They set an “overweight” rating and a $75.00 target price for the company.

Enliven Therapeutics Trading Down 6.8%

Shares of Enliven Therapeutics stock opened at $42.39 on Friday. The firm’s 50 day simple moving average is $54.86 and its two-hundred day simple moving average is $47.62. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -25.38 and a beta of 0.24. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, sell-side analysts predict that Enliven Therapeutics will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, Director Mika Derynck sold 158,795 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the transaction, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30. Following the transaction, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at $1,913,300. This represents a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 189,849 shares of company stock worth $11,140,085. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. KBC Group NV acquired a new position in Enliven Therapeutics during the first quarter valued at $38,000. State of Wyoming acquired a new stake in Enliven Therapeutics during the 2nd quarter worth about $96,000. FNY Investment Advisers LLC acquired a new stake in Enliven Therapeutics during the 2nd quarter worth about $126,000. WINTON GROUP Ltd purchased a new position in shares of Enliven Therapeutics during the 2nd quarter valued at about $228,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter valued at about $259,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.